Cardiac-specific expression of PPARβ/δ increased myocardial glucose utilization, prevented lipotoxic cardiomyopathy, and significantly reduced myocardial ischemia/reperfusion injury (infarct size 42.8% vs 59.9% in controls).
Absolute Event Rate: 42.8% vs 59.9%
p-value: p=<0.05
In the diabetic heart, chronic activation of the PPARalpha pathway drives excessive fatty acid (FA) oxidation, lipid accumulation, reduced glucose utilization, and cardiomyopathy. The related nuclear receptor, PPARbeta/delta, is also highly expressed in the heart, yet its function has not been fully delineated. To address its role in myocardial metabolism, we generated transgenic mice with cardiac-specific expression of PPARbeta/delta, driven by the myosin heavy chain (MHC-PPARbeta/delta mice). In striking contrast to MHC-PPARalpha mice, MHC-PPARbeta/delta mice had increased myocardial glucose utilization, did not accumulate myocardial lipid, and had normal cardiac function. Consistent with these observed metabolic phenotypes, we found that expression of genes involved in cellular FA transport were activated by PPARalpha but not by PPARbeta/delta. Conversely, cardiac glucose transport and glycolytic genes were activated in MHC-PPARbeta/delta mice, but repressed in MHC-PPARalpha mice. In reporter assays, we showed that PPARbeta/delta and PPARalpha exerted differential transcriptional control of the GLUT4 promoter, which may explain the observed isotype-specific effects on glucose uptake. Furthermore, myocardial injury due to ischemia/reperfusion injury was significantly reduced in the MHC-PPARbeta/delta mice compared with control or MHC-PPARalpha mice, consistent with an increased capacity for myocardial glucose utilization. These results demonstrate that PPARalpha and PPARbeta/delta drive distinct cardiac metabolic regulatory programs and identify PPARbeta/delta as a potential target for metabolic modulation therapy aimed at cardiac dysfunction caused by diabetes and ischemia.
Burkart et al. (Wed,) conducted a other in Myocardial metabolism and ischemia/reperfusion injury. Cardiac-specific expression of PPARβ/δ (MHC-PPARβ/δ) vs. Non-transgenic (NTG) littermates and MHC-PPARα mice was evaluated on Myocardial ischemia/reperfusion injury (infarcted area relative to area at risk [IA/AAR]) (p=<0.05). Cardiac-specific expression of PPARβ/δ increased myocardial glucose utilization, prevented lipotoxic cardiomyopathy, and significantly reduced myocardial ischemia/reperfusion injury (infarct size 42.8% vs 59.9% in controls).